Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:4 Issue:12 Number:35 ISSN#:2563-5476
RCT
ACE Report #7395
Ace Report Cover General Orthopaedics

Alendronate treatment for fibrous dysplasia, a rare skeletal disorder


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of Bone

J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.

Contributing Authors: AM Boyce MH Kelly BA Brillante H Kushner S Wientroub M Riminucci P Bianco PG Robey MT Collins

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

40 patients (24 adults and 16 children) with fibrous dysplasia (FD) were randomized to either receive alendronate administration in 6-month cycles for 24 months or placebo. The results revealed that in the alendronate group, NTX-telopeptides markers significantly declined at 18 months, however no significant difference in osteocalcin was observed between groups. Furthermore, areal bone mineral den...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.